Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03247972 · ClinicalTrials.gov registry record
Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease
A clinical trial, sponsored by Inova Health Care Services.
- Terminated
- Registry status
- 30
- Enrollment target
NCT03247972: Clinical Trial study, sponsored by Inova Health Care Services.
NCT03247972 is a clinical trial that was terminated before completion, run by Inova Health Care Services. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03247972 was terminated before completion, sponsored by Inova Health Care Services.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This investigation will be conducted in subjects \>18 years of age with PAD. Platelet activation and aggregation, and biomarkers associated with platelet activation, oxidative stress, and inflammation will be assessed prior to initiation of study-HD statin therapy (baseline), after 8 weeks of high-dose statins and 24 hours and 8 weeks after high dose statin + evolocumab therapy
Primary Outcome
Mean difference between 5uM ADP-induced % maximum platelet aggregation between V2 \[after run-in period / 8 weeks of HD statin therapy\] and V5 \[end of study/ 8 weeks o\]f continued HD statin therapy + evolocumab\]
Interventions
- DRUG Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-08-11 |
| Est. Completion | 2019-10-01 |
Why NCT03247972 stopped before completion
NCT03247972 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Evolocumab is the first listed.
NCT03247972 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03247972 about?
NCT03247972 is a clinical study titled "Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease". This investigation will be conducted in subjects \>18 years of age with PAD. Platelet activation and aggregation, and biomarkers associated with platelet activation, oxidative stress, and inflammation will be assessed prior to initiation of study-HD statin therapy (baseline), after 8 weeks of high-d...
What is the current status of trial NCT03247972?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2017-08-11. Estimated completion is 2019-10-01.
What interventions are being tested in trial NCT03247972?
The interventions under investigation include: Evolocumab (DRUG).
Who is sponsoring clinical trial NCT03247972?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI